Helen Hayes: To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the levels of stock of Evusheld held by NHS England.
Andrew Gwynne: To ask the Secretary of State for Health and Social Care, if he will take steps to expedite the rollout of Evusheld.
Sarah Olney: To ask the Secretary of State for Health and Social Care, whether his Department has made a decision on the (a) procurement and (b) planned extent of availability of Evusheld.
Andrew Gwynne: To ask the Secretary of State for Health and Social Care, whether the additional testing of Evusheld has now been completed.
Feryal Clark: To ask the Secretary of State for Health and Social Care, when the results of testing by the UKHSA on Evusheld’s effectiveness against the Omicron variant will be published.
Lord Mendelsohn: To ask Her Majesty's Government, further to the recent reported increase in COVID-19 infections, what plans they have to expedite the procurement of Evusheld.
Lord Mendelsohn: To ask Her Majesty's Government, further to the approval of Evusheld by the Medicine and Healthcare products Regulatory Agency on 17 March, when they plan to announce their policy on the provision of Evusheld; and if they are not yet ready to make an announcement, what progress they have made on developing the clinical commissioning policy for Evusheld.
Helen Hayes: To ask the Secretary of State for Health and Social Care, what steps is he taking to increase the availability of Evusheld to immunocompromised people in the event of future waves of covid-19.
Andrew Gwynne: To ask the Secretary of State for Health and Social Care, when Evusheld will be available for eligible patients.
Lord Tyrie: To ask Her Majesty's Government what assessment they have made of the use of Evusheld by other countries; and what data they have received on that drug’s efficiency at combatting the effects of COVID-19.
Lord Tyrie: To ask Her Majesty's Government what assessment they have made of the efficacy of Evusheld on the protection of patients with metastatic cancer from COVID-19.
Daisy Cooper: To ask the Secretary of State for Health and Social Care, with reference to the Answer of 20 April 2022 to Question 151279, on Evusheld, whether the UKHSA has reviewed studies published by the US Food and Drug Administration and European Medicines Agency on the effectiveness of Evusheld against the covid-19 omicron variant; and for what reason the UKHSA has decided to undertake duplicate...
Lord Tyrie: To ask Her Majesty's Government what estimate they have made of the number of immunocompromised individuals who would benefit from access to Evusheld if it became available.
Daisy Cooper: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 April 2022 to Question 151279 on Evusheld, when the UKHSA began testing Evusheld’s effectiveness against the covid-19 omicron variant; and whether UKHSA has guidance on how long that testing should take.
Lord Tyrie: ...Written Answer by the Parliamentary Under Secretary of State for the Department of Health and Social Care on 7 June (1507), when they expect the UK Health Security Agency (UKHSA) testing review of Evusheld to be completed.
Bell Ribeiro-Addy: To ask the Secretary of State for Health and Social Care, what role the cost of medication plays in the Government's decision to procure (a) Evusheld, (b) Beblitovimab and (c) other drugs.
Jessica Morden: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 8 June 2022 to Question 1109 on Evusheld, what his planned timetable is for (a) receiving advice from clinicians on the most appropriate option for the use of Evusheld and (b) procuring that treatment for use within the NHS.
Philippa Whitford: To ask the Secretary of State for Health and Social Care, what his planned timetable is for making a decision on the use of Evusheld following conclusion of UKHSA testing.
Tulip Siddiq: To ask the Secretary of State for Health and Social Care, on what date the UK Health Security Agency plans to complete testing on Evusheld’s efficacy against the omicron variant of covid-19; and what steps his Department plans to take to notify immunocompromised people that they are eligible for that treatment in the event that it is authorised.
Bob Blackman: ...of authorisation for the use of Sotrovimab for treatment of covid-19 on 5 April 2022, what steps he is taking to ensure the (a) stringency and (b) consistency of his Department's reviews of (i) Evusheld and (ii) other covid-19 treatments.